Long-term studies made simple and scalable

Long-term studies
made simple
and scalable

Embleema unifies complex, multimodal patient data for Phase IV and non-interventional research—delivering compliant, complete evidence at 40% lower cost.

See the platform

Request a demo

Our Clients

For sponsors

Launch and manage registries in weeks
vs months

Info for sponsors

For sites

Streamline workflows and reduce drop‑off to under 1%

Info for sites

For patients

Engaged participants with 90%+ ePRO response

Info for patients

Embleema’s integrated platform captures and unifies the multimodal data others don’t.

Sponsors generate regulatory-grade real-world data through a single customizable platform combining patient and site apps with genomic, clinical, and self-reported data, delivering multimodal datasets in weeks.

Configure in days

We implement your protocol using no-code, drag-and-drop modules tailored to your condition—then adapt as your study evolves, without added overhead.

Audit-ready data capture, live from day one

Pull ePRO, wearable, site, and EHR data into a real-time, audit-ready database from day one with every field source-tracked for auditability.

Stay connected to each patient, year after year

Rich health data logs and clinical trial research opportunities keep participants engaged, resulting in better care and deeper study insights.

See more features

Real-world evidence for complex diseases feels impossible to gather, until now

First, close every data gap.

Our system ingests structured and unstructured data from sites and patients, enriched with records from 60,000+ care centers and 550+ wearables, backed by a consent system that ensures compliance and transparency.

A doctor talking to a patient and a screenshot of the participant list in the Embleema platform

First, close every data gap.

A medical professional on her smartphone with a laptop on the desk and a screenshot of the study tracker in the Embleema platform

Skip the custom and labor-intensive build bill

Say goodbye to the patchwork of solutions. Even for the most complex protocols, you can launch fast with our no-code tools and expert team—no extra coding, integrations, or CRO support required.

Skip the custom and labor-intensive build bill

Onboard in days, engage them for years—patients thrive as research partners.

Real-time nudges, personalized insights, and shareable health reports motivate participants to keep logging and actively sharing data, maintaining strong engagement.

A doctor talking to a patient and a screenshot of "seizures reported" in the Embleema platform

Onboard in days, engage them for years—patients thrive as research partners.

Real-time nudges, personalized insights, and shareable health reports motivate participants to keep logging and actively sharing data, maintaining strong engagement.

Onboard in days, engage them for years—patients thrive as research partners.

Real-time nudges, personalized insights, and shareable health reports motivate participants to keep logging and actively sharing data, maintaining strong engagement.

A professional going over data and numbers, and a screenshot of the dashboard for sponsors on Embleema

Finally, streamline access to the dataset of your dreams, in real time.

No manual data reconciliation or delayed “data cuts”, run studies at a fraction of CRO costs with real-time access and follow-up from our patient communities.

Finally, streamline access to the dataset of your dreams, in real time.

No manual data reconciliation or delayed “data cuts”, run studies at a fraction of CRO costs with real-time access and follow-up from our patient communities.

Finally, streamline access to the dataset of your dreams, in real time.

No manual data reconciliation or delayed “data cuts”, run studies at a fraction of CRO costs with real-time access and follow-up from our patient communities.

Results that matter

“Embleema’s platform provides the unique ability of allowing our community to better manage their condition in a user friendly manner, while at the same time, providing researchers with valuable, interpretable real-world data.”